Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 8mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 8mg Reference Tablet of Candesartan Cilexetil (Atacand) in Healthy Adult Human Subjects Under Fasting Conditions

NCT02006589 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02006589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02006589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 8mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 8mg Reference Tablet of Candesartan Cilexetil (Atacand) in Healthy Adult Human Subjects Under Fasting Conditions
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
December 11, 2013
Completion date
January 22, 2014
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension